Jan Bergman
Associate Director
Medical Science
Oxypharma
Sweden
Biography
Professor and Group leader at the Center for Nutrition and Toxicology, Karolinska Institute. Associate Professor in Organic Chemistry with the Royal Institute of Technology, Stockholm. Previous employments include: Chemistry/patent consultant for AstraZeneca, Medivir and Karo Bio and acting as technical judge in patent trials. Former President and Board member of the International Society of Heterocyclic Chemistry. Involvement with OxyPharma: Dr. Bergman initiated the anti-viral research with B-220 in the 1970's and is the chemist behind B-220 and its related analogues. He is currently actively involved and has e.g. synthesized the analogues of B-220 and contributed to the protection of OxyPharma's intellectual property rights.
Research Interest
His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.
